EMD Serono Research & Development Institute, Inc.

Pharma

Rockland, Massachusetts, USA, United States · Est. 1990

EMD Serono Research & Development Institute, Inc. is a subsidiary of Merck KGaA (Darmstadt, Germany) focused on discovering and developing pharmaceutical treatments in oncology, neurology, and immunology.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

101

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Phase 31

Phase 14

By Therapeutic Area

top 3

Oncology

360%

Immunology

120%

Nephrology

120%

R&D Momentum

52/100

Pipeline Velocity

22/100

Trial Completion Rate

60/100

Pipeline Concentration

44/100

Pipeline Freshness

69/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 5, 2026

Recruiting

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M0324, a Bispecific (MUC-1 x CD40) Antibody as Monotherapy, in Combination With Pembrolizumab, and in Combination With Chemotherapy, in Participants With Selected Advanced Solid Tumors

Oct 30, 2026

Recruiting

Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

Oct 23, 2026

Active, not recruiting

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

Earlier

Oct 21, 2026TrialA Phase 1, 2-Part, Multicenter, Open-Label, First-in-Human Study of the Anti-Ly6E Exatecan Antibody-Drug Conjugate M7437 in Participants With Advanced Solid Tumors

Oct 9, 2026TrialA Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Oct 8, 2026TrialA Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors

4 more events

Sep 29, 2026TrialA Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)

Sep 26, 2026TrialA Phase 3, Single-Arm, Open-Label, Long-Term Extension Study To Evaluate The Safety And Efficacy Of Enpatoran In Participants With Active Cutaneous Manifestations Of Lupus Erythematosus With Or Without Systemic Disease Receiving Standard Of Care [Elowen-LTE]

Sep 23, 2026TrialAn Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies

Sep 15, 2026TrialAn Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deﬁciency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)

Details